Versus Arthritis Award News
Posted on: 23 February 2021 by Jenna Gritzfeld & Laura Whitty in 2021 posts
We are excited to share that Versus Arthritis have awarded us; the UK’s Experimental Arthritis Treatment Centre for Children (EATC4Children) a further three years of funding to continue the great strides we’ve already made to help develop new and better treatments for childhood arthritis and related conditions.
What is the EATC4Children?
We are based in Liverpool at Alder Hey Children’s NHS Foundation Trust and the University of Liverpool. We work in close partnership with colleagues at the University of Sheffield, University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust.
Our goals are focused on:
- improving the health and wellbeing of children and young people with arthritis and related conditions.
- identifying and testing new treatments specifically targeted at children, with a focus on therapies not yet tested in children, including early laboratory-based studies and clinical trials.
All of the work carried out in the centre is inspired by and involves children, young people affected by arthritis, and their families, and the research is always directed towards answering the priority questions they have.
What do we mean by experimental research?
Experimental medicine is an area of research that bridges the gap between basic research and clinical trials, so taking early research from the lab and into people.
This area of research allows us to get a better understanding of how the body works in healthy individuals compared to how this changes in disease. Thanks to advances in technology, we are now better able to study this in people, which will allow fascinating new insights into disease mechanisms.
How is the centre involving and helping children and their families?
Lily Whitehead is just one volunteer that has participated in EATC4Children studies including the SYCAMORE trial, which tested the effectiveness of the drug Adalimumab for the treatment of juvenile arthritis-associated uveitis.
Talking about her experience of being part of the study, Lily said
“I used to have to take tablets that made me feel ill. The injections (Adalimumab) hurt a little bit but were so much better than the tablets.
“Once I started taking the injections, my joints and eyes got better really quickly. Now, we are able to do the injections at home and it makes life a lot easier, we don’t have to keep travelling to the hospital.
“The teams at the centre were so kind, they helped me a lot and it was nice knowing they were there to talk to. It was a really positive thing being part of a research study”.
What has the centre already achieved?
We lead a wide range of studies addressing the needs of children and young people with arthritis, arthritis-associated uveitis, lupus, scleroderma, metabolic, inflammatory and orthopaedic bone-related conditions, and a number of other disease areas including childhood Behcet’s disease, dermatomyositis and renal inflammatory disorders.
Highlights so far include:
- Improving treatment for children with uveitis– the APTITUDE trial is a landmark trial developed and delivered by the team at the EATC4Children. It aimed to find the best way to treat children with the most extreme and severe eye inflammation associated with childhood arthritis (uveitis) that had failed all other treatments, including even anti-TNF therapy.
- Collaboration in the field – the EATC4Children has been part of the enormously important and successful bid to form the MRC Stratified Medicine CLUSTER Consortium and leads its Uveitis and Industry workstreams.
The trial provided evidence that tocilizumab might be a useful adjunctive therapeutic option for children with uveitis refractory to anti-TNF treatments.
This collaborative initiative brings together the UK’s leading childhood arthritis and uveitis experts to help personalise treatment, find and test new treatments, and predict disease outcomes for childhood arthritis and uveitis.
- Leading research into childhood lupus – lupus in children is known to be generally more severe than in adults, causing more damage and needing more intense treatments, and can affect any of the body’s organs having a life-changing impact on those affected.
We lead a major program of translational research, supporting one of the largest national cohorts of patients with lupus in the world with over 750 patients now recruited, identifying markers in the body that identify whether you will respond to treatments for tackling this complex disease.
Dr Neha Issar-Brown, Versus Arthritis’ new Director of Research comments:
“The UK’s EATC4Children has already made great strides in improving our care and understanding of childhood autoimmune conditions.
What is commendable is that all of their work is inspired by and involves children, young people, and their families, and is always directed towards answering the priority questions they have. This speaks to Versus Arthritis' ambition to ensure our research is aligned with the impact on individuals, especially children and young people - an otherwise overlooked demographic.
We are delighted to continue our partnership with the EATC4Children, an enormously important research centre helping to deliver our commitment and goal to support experimental medicine, which can transform the lives of children affected by arthritis and related conditions”.
How will this renewed funding make a difference?
Professor Michael Beresford, Director of the EATC4Children explains:
“The UK’s EATC4Children has been instrumental over the past six years, nationally and internationally, in tackling these major inflammatory conditions affecting children and young people.
“This renewed commitment from Versus Arthritis enables us to take forward our world-leading translational biomedical research (bench-to-bedside and back again) that helps us improve our understanding, our care and most importantly, the health and wellbeing of children and young people growing up with these life-changing disorders.”
Professor A. V. Ramanan, Associate Director of the EATC4Children, Professor of Paediatric Rheumatology at the University of Bristol and Consultant Paediatric Rheumatologist at Bristol Royal Hospital for Children added:
"The EATC for children has been pivotal in enabling translational research for children with rheumatic diseases. Working in partnership with colleagues from industry and academia, we hope that the continued funding will help take forward the progress made so far.”
Professor Nick Bishop, Associate Director of the EATC4Children and Professor of Paediatric Bone Disease at the University of Sheffield added:
"We are very grateful to Versus Arthritis for this continued commitment to the EATC for Children. The award will enable us to continue to support the development of vital capability and capacity in this field through our training programme work in collaboration with our partners - the Academic Paediatric Association of Great Britain and Ireland, and the Royal College of Paediatrics and Child Health - as well as supporting early-stage, translational and biomarker work in children with skeletal diseases such as osteoporosis, sadly a frequent accompaniment to inflammatory arthritis."
Louise Shepherd, Chief Executive at Alder Hey said:
"Alder Hey Children's Hospital are absolutely delighted at the news. We are very proud that the UK’s Experimental Arthritis Treatment Centre for Children is based here at Alder Hey. We know that arthritis in children, and other rheumatic conditions, can be very debilitating. The more research we can do linking directly the bench-to-bedside into helping improve our understanding, care and the quality of life and outcomes for children, the better. Through partnership working, we can help achieve better outcomes for children in the region, across the UK and beyond".
Professor Louise Kenny, Executive Pro-Vice-Chancellor, Faculty of Health and Life Sciences at the University of Liverpool states:
“The University of Liverpool is delighted that the flagship UK ‘Experimental Arthritis Treatment Centre for Children’ (EATC4Children) has been renewed for a further three years. The health and wellbeing of children and young people locally, nationally and indeed globally is a key strategic research priority for the University. We are therefore honoured to partner with Alder Hey on this critical initiative which seeks to provide innovation and impact and to alleviate the significant burden of morbidity associated with these devastating and often neglected diseases. Under the inspirational leadership of Professor Michael Beresford, the EATC4Children has become a beacon of translational research excellence and we are proud to support the critical contribution of this centre and Professor Beresford and his team.”